2023-11-27 11:00:00
The CellForCure bioproduction plant in Les Ulis (Essonne) has a future. Founded by LFB in 2013 then acquired by Novartis in 2019, this strategic site for the production of biomedicines in France is changing hands once more. On November 27, 2023, Seqens formalized the purchase of the site, effective from December 1, which will be renamed CellForCure by Seqens. The amount of the acquisition remains confidential. The 180 employees of the factory change employers and all the infrastructure is taken over. Originally focused on subcontracting before becoming entirely devoted to Novartis production, the site will once once more be repositioned as a specific custom production center, whether for the development or manufacturing up to the commercial scale of biomedicines. , on behalf of academic laboratories, biotechnology companies or large pharmaceutical groups.
Seqens entry into the cell and gene therapy market
For Seqens (3,500 employees, more than 1.3 billion euros in turnover in 2022), this operation negotiated since last summer marks a “new step, it is a first step towards cell and gene therapies which complements our positioning on small molecules and the production of active ingredients and pharmaceutical intermediates», Comments Gildas Barreyre, general secretary of the group. Producer but also subcontractor for pharmaceutical development and contract production (CDMO), Seqens will considerably broaden its scope of activities by integrating the bioproduction market, where capacities are strategic but are still undersized in France.
[…]
This article is reserved for our L’Usine Nouvelle subscribers
Support expert journalism.
Log in
VOS INDICES
source
Selected for you
1701106491
#Les #Ulis #Seqens #succeeds #Novartis #CellForCure #factory #specialist #biomedicines
